Four Hot Biotechs Among The Day’s Big Winners

Let’s start with Pacira Pharmaceuticals Inc (NASDAQ:PCRX), which is up by 5.85% today. As covered in the aforementioned article, Pacira Pharmaceuticals Inc (NASDAQ:PCRX) was one of eight small-cap stocks pegged by Goldman Sachs as having double-digit top-line growth potential over the next two years, while also doubling its operating earnings between 2014 and 2017. Of those eight stocks, we focused on five which also had very strong sentiment among the elite investors that we track. By that criteria, Pacira ranked fourth on the list, with 25 investors holding over $367 million of the company’s shares, over 14% of its outstanding stock. Goldman Sachs has a ‘Buy’ rating and $90 price target on the stock, while Nomura reiterated its own ‘Buy’ rating and identical $90 price target on Sunday. That price target represents nearly 125% upside potential. John Lykouretzos’ Hoplite Capital Management is one investment firm that would surely be pleased with such gains, holding over 1.26 million shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) on June 30.

Lastly is Zeltiq Aesthetics Inc (NASDAQ:ZLTQ), which ranked third on the aforementioned list. 26 investors we track held nearly 31% of the company’s common shares on June 30, worth over $352 million. The developer of CoolSculpting, a non-invasive fat reduction system, Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) is up by 7.17% in trading today. The company will release its third quarter earnings next Tuesday, with the market expecting an earnings per share loss of $0.03, after it earned $0.03 per share in the second quarter. Steve Cohen, Israel Englander, and Ken Griffin are a few of the elite investors we follow that hold long positions in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ).

Disclosure: None